Learn More
BACKGROUND Combination therapy with alendronate and estrogen for 2 years increases bone mineral density at the spine and hip more than does therapy with either agent alone. Changes in bone mineral(More)
Long-term treatment studies showed that the therapeutic effects of alendronate (ALN) were sustained over a 10-year treatment period. However, data on the effects on intrinsic bone material properties(More)
AIM This study aimed to evaluate the safety, pharmacokinetics and treatment effects of an alpha(nu)beta(3) integrin inhibitor on bone turnover and disease activity in men with hormone-refractory(More)